RxDoctor Payments DataLook up a doctor →

Lawrence Lazar, MD

Cardiovascular Disease · Lakewood, CONPI 1730204678

Payments from drug & device makers

$46,010in general payments, 2019–2025

Across 456 payments — averaging $100.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$36K
  • Medtronic$2K
  • Amgen$826
  • Abbott$761
  • Pfizer$696
  • Abiomed$614
  • plus $6K from 44 others

What the payments were for

  • Consulting fees$270%
  • Speaking & faculty fees$32,00070%
  • Travel & lodging$5591%
  • Food & beverage$13,16129%
  • Education$390%
  • Other$2240%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$46,010 in reported general payments places this provider in the 85th percentile of 276 cardiovascular disease providers in Colorado.

See all cardiovascular disease providers in Colorado

Medicare billing

Part B allowed, 2024
$207,760
Medicare patients
879
Services billed
2,348

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban365$440,394
EntrestoSacubitril/Valsartan43$72,597
Repatha SureclickEvolocumab68$51,068
XareltoRivaroxaban51$49,734
JardianceEmpagliflozin28$26,054
FarxigaDapagliflozin Propanediol20$17,279
Praluent PenAlirocumab24$14,552
BrilintaTicagrelor16$11,794
Rosuvastatin Calcium356$4,715
Amlodipine-ValsartanAmlodipine Besylate/Valsartan35$4,616
Atorvastatin Calcium442$4,185
Metoprolol Succinate375$3,839
Flecainide Acetate105$3,540
Nebivolol Hcl50$3,232
Ezetimibe91$2,420

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$696$440,394365 claims
NovartisEntresto$449$72,59743 claims
Johnson & JohnsonXarelto$545$49,73451 claims
AstraZenecaFarxiga, Brilinta$363$29,07336 claims
Boehringer IngelheimJardiance$341$26,05428 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 276 cardiovascular disease providers in Colorado.

Other cardiovascular disease in Lakewood

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →